GlaxoSmithKline, Theravance Say FDA Accepts FF/VI NDA Submission for COPD

GlaxoSmithKline and Theravance announced the FDA acceptance of the NDA for the once-daily investigational medicine fluticasone furoate for patients with chronic obstructive pulmonary disease or COPD, thereby indicating that the application is sufficiently complete to permit a substantive review.
RTTNews